查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1615463

格雷夫兹病市场：按诊断、治疗、给药途径、分销管道和最终用户分类 - 全球预测 2025-2030

Graves Disease Market by Diagnosis (Blood Tests, Imaging Tests, Physical Examination), Treatment (Adjunctive Treatments, Medications, Radioactive Iodine Therapy), Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年格雷夫兹病市场价值为5.8385亿美元，预计到2024年将达到6.1351亿美元，复合年增长率为5.42%，到2030年将达到8.4489亿美元。

格雷夫兹病市场范围和定义涵盖了对这种以甲状腺激素过量产生为特征的自体免疫疾病的全面分析。这种需求源于其普遍存在以及对有效的诊断和治疗方法来管理甲状腺功能亢进、眼科疾病和皮肤病等疾病的需求。最终用途主要包括医院、诊所和研究机构。推动市场成长的主要影响因素包括发病率增加、先进的诊断能力以及对自体免疫疾病的日益关注。其中蕴藏丰富的商机，包括生物製药、免疫疗法等新型治疗剂的开发，以及利用人工智慧进行早期诊断等。对个人化医疗和以患者为中心的护理模式的投资有可能显着推动成长，特别是在医疗保健成本增加的情况下。然而，其局限性仍然存在，例如治疗费用高、现有药物的副作用以及自体免疫疾病的复杂性，这些可能会阻碍其广泛使用。此外，监管障碍和需要大规模临床试验来证明有效性和安全性等挑战仍然是重大问题。为了加强对格雷夫兹病的认识和治疗，我们需要专注于分子层次的研究，探索遗传倾向和环境触发因素。市场参与企业应优先考虑与研究机构合作，以推动新製剂和诊断工具的研发。在医疗政策变化和技术进步的支持下，格雷夫兹病市场持续缓慢但稳定的成长。公司需要紧跟监管变化，并努力透过生物相似药等创新来降低治疗成本。策略伙伴关係、产品多元化和进入新兴国家市场可以增加市场潜力。此外，我们以患者为中心的方法和治疗方案教育可以透过提高患者的依从性和结果、提高品牌信任和忠诚度来帮助建立市场领导地位。

主要市场统计
基准年[2023] 5.8385亿美元
预计年份 [2024] 61351万美元
预测年份 [2030] 84489万美元
复合年增长率（%） 5.42%

市场动态：针对快速发展的格雷夫兹病市场揭示的关键市场洞察

供需的动态交互作用正在改变格雷夫兹病市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球自体免疫疾病盛行率上升
    • 在政府主导提高公众意识
    • 个人化医疗需求不断成长
  • 市场限制因素
    • 与先进治疗方法和诊断相关的高成本
  • 市场机会
    • 活性化先进治疗药物的研发活动
    • 建立研究机构与生技公司之间的合作关係
  • 市场挑战
    • 法规环境严峻、核准程序复杂

波特的五力：驾驭格雷夫兹病市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解格雷夫兹病市场的外部影响

外部宏观环境因素在塑造格雷夫兹病市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解格雷夫兹病市场的竞争状况

格雷夫兹病市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵格雷夫兹病市场供应商的绩效评估

FPNV定位矩阵是评估格雷夫兹病市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了格雷夫兹病市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，格雷夫兹病市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球自体免疫疾病的盛行率上升
      • 随着政府措施的增加，公众意识也在增强
      • 个人化医疗需求不断成长
    • 抑制因素
      • 与先进治疗和诊断相关的高成本
    • 机会
      • 持续进行先进治疗方法的研究和开发活动
      • 研究机构与生技公司之间的新合作
    • 任务
      • 法规环境严格、核准程序复杂
  • 市场区隔分析
    • 治疗：放射性碘疗法在格雷夫兹病治疗的普及
    • 给药途径：静脉注射越来越多地用于格雷夫兹病的急性治疗
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 格雷夫兹病诊断市场

  • 验血
    • 免费 T4 和 T3 级别
    • 甲状腺刺激素(TSH) 水平
    • TSH 受体抗体 (TSH-RAb)
  • 影像检查
    • CT 或 MRI 扫描
    • 摄入放射性碘
    • 甲状腺超音波检查
  • 体检

第七章格雷夫兹病市场的治疗

  • 辅助治疗
  • 药品
    • 抗甲状腺药物
    • β受体阻断剂
      • 阿替洛尔
      • Propranolol
  • 放射性碘治疗
  • 外科手术

第八章格雷夫兹病市场：依给药途径

  • 静脉
  • 口服
  • 手术介入

第九章格雷夫兹病市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房
  • 专业药房

第 10 章 格雷夫兹病市场：依最终用户分类

  • 医疗服务提供方
  • 医院/诊所
  • 个别患者

第十一章 美洲格雷夫兹病市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区格雷夫兹病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲格雷夫兹病市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • IBSA USA 续签了与高尔夫球手 Azahara Muñoz 的合作关係，以提高 Tirosint-SOL 的知名度，Tirosint-SOL 是一种经 FDA核准的甲状腺机能低下症治疗药物，具有无与伦比的灵活性和便利性。
    • 信达生物抗IGF-1R抗体IBI311在中国获得甲状腺眼疾的优先审评，支持重大临床进展与全球扩张
    • 随着欧盟核准甲状腺眼疾治疗 teprotumumab，安进开始在格雷夫兹病治疗方面取得进展，并计划长期市场扩张和加强患者照护
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • AdvanceCor GmbH
  • Amgen Inc.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Immunovant, Inc.
  • Jubilant Pharma Holdings Inc.
  • Lannett Company, Inc.
  • Lupin Limited
  • Medtronic PLC
  • Merck KGaA
  • Novartis AG
  • Omeros Corp
  • OSE Immunotherapeutics SA
  • Protheragen Inc
  • RLC Labs, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.
  • Zenas BioPharma, Inc.
Product Code: MRR-42653751EADD

The Graves Disease Market was valued at USD 583.85 million in 2023, expected to reach USD 613.51 million in 2024, and is projected to grow at a CAGR of 5.42%, to USD 844.89 million by 2030.

The scope and definition of the Graves' Disease market encompass a comprehensive analysis of this autoimmune disorder characterized by overproduction of thyroid hormones. The necessity stems from its prevalence and the need for effective diagnostics and therapeutics to manage symptoms like hyperthyroidism, eye diseases, and skin conditions. The application involves pharmaceuticals, diagnostics, and personalized medicine, while the end-use scope primarily includes hospitals, clinics, and research institutes. Key influencing factors driving market growth include increasing incidence rates, advanced diagnostic capabilities, and a growing focus on autoimmune diseases. Opportunities abound in developing novel therapeutics, such as biologics and immunotherapies, and leveraging AI for early diagnosis. Investing in personalized medicine and patient-centric care models can significantly drive growth, especially with rising healthcare spending. However, limitations persist, like the high cost of treatment, side effects of current medications, and the complexity of autoimmune conditions, potentially hindering widespread adoption. Moreover, challenges such as regulatory hurdles and the need for extensive clinical trials to prove efficacy and safety remain pivotal issues. Innovation should focus on molecular-level research, exploring genetic predispositions and environmental triggers to enhance understanding and treatment of Graves' Disease. Market participants should prioritize collaborations with research institutions to drive R&D in novel drug formulations and diagnostic tools. The nature of the market leans towards moderate but consistent growth, tethered by healthcare policy changes and technological advancements. Companies should stay abreast of regulatory shifts and work towards reducing treatment costs through innovations like biosimilars. Strategic partnerships, product diversification, and market entry in emerging economies could ramp up market potential. Additionally, a patient-focused approach and education about treatment options could foster better patient adherence and outcomes, establishing market leaders through enhanced brand trust and loyalty.

KEY MARKET STATISTICS
Base Year [2023] USD 583.85 million
Estimated Year [2024] USD 613.51 million
Forecast Year [2030] USD 844.89 million
CAGR (%) 5.42%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Graves Disease Market

The Graves Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of autoimmune disorders globally
    • Increasing awareness among population with rising government initiatives
    • Growing demand for personalized medecine
  • Market Restraints
    • High cost associated with advanced therapeutics and diagnostics
  • Market Opportunities
    • Ongoing research and development activities for advanced therapies
    • Emerging collaboration between research institutes and biotech firms
  • Market Challenges
    • Stringent regulatory environments and complex approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Graves Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Graves Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Graves Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Graves Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Graves Disease Market

A detailed market share analysis in the Graves Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Graves Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Graves Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Graves Disease Market

A strategic analysis of the Graves Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Graves Disease Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AdvanceCor GmbH, Amgen Inc., Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GSK plc, Immunovant, Inc., Jubilant Pharma Holdings Inc., Lannett Company, Inc., Lupin Limited, Medtronic PLC, Merck KGaA, Novartis AG, Omeros Corp, OSE Immunotherapeutics SA, Protheragen Inc, RLC Labs, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Viatris Inc., and Zenas BioPharma, Inc..

Market Segmentation & Coverage

This research report categorizes the Graves Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Diagnosis, market is studied across Blood Tests, Imaging Tests, and Physical Examination. The Blood Tests is further studied across Free T4 & T3 Levels, Thyroid-Stimulating Hormone (TSH) Levels, and TSH Receptor Antibodies (TSH-RAb). The Imaging Tests is further studied across CT or MRI Scans, Radioactive Iodine Uptake, and Thyroid Ultrasound.
  • Based on Treatment, market is studied across Adjunctive Treatments, Medications, Radioactive Iodine Therapy, and Surgery. The Medications is further studied across Anti-thyroid Drugs and Beta-Blockers. The Beta-Blockers is further studied across Atenolol and Propranolol.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Surgical Intervention.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Pharmacies.
  • Based on End User, market is studied across Healthcare Providers, Hospitals & Clinics, and Individual Patients.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of autoimmune disorders globally
      • 5.1.1.2. Increasing awareness among population with rising government initiatives
      • 5.1.1.3. Growing demand for personalized medecine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced therapeutics and diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development activities for advanced therapies
      • 5.1.3.2. Emerging collaboration between research institutes and biotech firms
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environments and complex approval procedures
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Proliferation of radioactive iodine therapy for Graves' disease treatment
    • 5.2.2. Route of Administration: Growing application of intravenous administration for acute management of Graves' disease
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Graves Disease Market, by Diagnosis

  • 6.1. Introduction
  • 6.2. Blood Tests
    • 6.2.1. Free T4 & T3 Levels
    • 6.2.2. Thyroid-Stimulating Hormone (TSH) Levels
    • 6.2.3. TSH Receptor Antibodies (TSH-RAb)
  • 6.3. Imaging Tests
    • 6.3.1. CT or MRI Scans
    • 6.3.2. Radioactive Iodine Uptake
    • 6.3.3. Thyroid Ultrasound
  • 6.4. Physical Examination

7. Graves Disease Market, by Treatment

  • 7.1. Introduction
  • 7.2. Adjunctive Treatments
  • 7.3. Medications
    • 7.3.1. Anti-thyroid Drugs
    • 7.3.2. Beta-Blockers
      • 7.3.2.1. Atenolol
      • 7.3.2.2. Propranolol
  • 7.4. Radioactive Iodine Therapy
  • 7.5. Surgery

8. Graves Disease Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Surgical Intervention

9. Graves Disease Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies
  • 9.5. Specialty Pharmacies

10. Graves Disease Market, by End User

  • 10.1. Introduction
  • 10.2. Healthcare Providers
  • 10.3. Hospitals & Clinics
  • 10.4. Individual Patients

11. Americas Graves Disease Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Graves Disease Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Graves Disease Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. IBSA USA Renews Alliance with Golfer Azahara Munoz to Boost Awareness for FDA-Approved Tirosint-SOL, the Hypothyroidism Treatment Offering Unmatched Flexibility and Convenience
    • 14.3.2. Innovent Biologics' Advancement Anti-IGF-1R Antibody IBI311 Secures Priority Review for Thyroid Eye Disease in China, Supporting Major Clinical Advances and Global Expansion
    • 14.3.3. Amgen Moves to Advance Graves' Disease Treatment with EU Approval of Teprotumumab for Thyroid Eye Disease; Plans for Long-Term Market Expansion and Patient Care Enhancements
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. AdvanceCor GmbH
  • 4. Amgen Inc.
  • 5. Bayer AG
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. GSK plc
  • 9. Immunovant, Inc.
  • 10. Jubilant Pharma Holdings Inc.
  • 11. Lannett Company, Inc.
  • 12. Lupin Limited
  • 13. Medtronic PLC
  • 14. Merck KGaA
  • 15. Novartis AG
  • 16. Omeros Corp
  • 17. OSE Immunotherapeutics SA
  • 18. Protheragen Inc
  • 19. RLC Labs, Inc.
  • 20. Sanofi S.A.
  • 21. Teva Pharmaceutical Industries Ltd.
  • 22. Thermo Fisher Scientific Inc.
  • 23. Viatris Inc.
  • 24. Zenas BioPharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GRAVES DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. GRAVES DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GRAVES DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GRAVES DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GRAVES DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GRAVES DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY CT OR MRI SCANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADJUNCTIVE TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTI-THYROID DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GRAVES DISEASE MARKET SIZE, BY ATENOLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GRAVES DISEASE MARKET SIZE, BY PROPRANOLOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GRAVES DISEASE MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GRAVES DISEASE MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL GRAVES DISEASE MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL GRAVES DISEASE MARKET SIZE, BY INDIVIDUAL PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES GRAVES DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 298. NETHERLANDS GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 307. NIGERIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 316. NORWAY GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 325. POLAND GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 334. QATAR GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 340. RUSSIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 341. RUSSIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 342. RUSSIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 343. RUSSIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 345. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 346. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 347. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 348. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 349. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 350. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 351. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 352. SAUDI ARABIA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 353. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 354. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
  • TABLE 355. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 356. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 357. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 358. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 359. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 360. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 361. SOUTH AFRICA GRAVES DISEASE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 362. SPAIN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 363. SPAIN